Drug Trial Radar · NCT07585383
A Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of KR23248 Capsules in Healthy Adult Subjects
Last checked: Nov 20, 2026Latest source record: May 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
66
Planned (sponsor's estimate)
Start
May 19, 2026
Primary completion
Nov 2026
Study completion Nov 2026
Sponsor
- Lead sponsor
- Jiangxi Kvvit Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study aims to investigate the safety, tolerability and pharmacokinetic characteristics of KR23248 capsules in healthy subjects. This study will be conducted in China. It will enroll male and female participants aged 18 years to 45 years.
Conditions
- Schizophrenia
Interventions
KR23248Drug
Participants will recieve a single oral dose of KR23248
Matching PlaceboDrug
Participants will recieve placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events (AEs), serious adverse events(SAEs), drug-related AEs, and AEs leading to study withdrawalTime frame: SAD:Day 1 to Day14 MAD:Day1 to Day28
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.